17.05.2019 • NewsCodexisDede WillamsNovartis

Codexis Signs License Deal with Novartis

Codexis Signs License Deal with Novartis (c) Alex_Traksel/Shutterstock
Codexis Signs License Deal with Novartis (c) Alex_Traksel/Shutterstock

US protein engineering company Codexis has signed a platform agreement with Novartis, granting the Swiss pharmaceutical producer a non-exclusive license to its proprietary CodeEvolver protein technology.

Novartis will use the license to develop novel performance enzymes for use in drug manufacture. Upon completion of the technology transfer, the CodeEvolver protein engineering platform will be located at an undisclosed Novartis site.

Terms of the agreement foresee Novartis making an upfront payment, milestone payments upon the satisfactory completion of technology transfer and payments for improvements to the platform technology.

Redwood, California-based Codexis also will be eligible to receive payments for active pharmaceutical ingredients (APIs) produced with enzymes developed by Novartis using the CodeEvolver technology. Additionally, it will receive certain rights for future purchases of enzymes developed and sourced by the drugmaker, using the technology.

John Nicols, Codexis’ president and CEO said Novartis has been a “highly valued customer for nearly a decade, and we’ve been very pleased to see the accelerating and widening of our R&D collaborations together especially over the past several years.”

Novartis, said Nichols, will be the latest leading pharmaceutical company to validate the very wide applicability of enzymatic catalysis across its extensive small molecule drug pipeline.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.